VBI-S is an intravenously injectable fluid comprised of phospholipid nanoparticles that were specifically designed to shift the biophysical properties of the body's fluid volume in hypovolemic shock, due to sepsis, from non-survival to survival.
However, a high possibility of compartment syndrome due to gushing of fluids and drugs into soft tissues; limitations in the case of individuals with severe osteoporosis and hypovolemic conditions; and impediment of IO infusion devices after arrival of vein viewer are factors likely to restrict market growth over the forecast period.
A loss of enough fluid can cause life-threatening shock due to a low blood volume (hypovolemic shock) due to a drop in blood pressure and low oxygen levels (from a reduced oxygencarrying capacity of the increasingly thickened blood).
Ischemic heart disease, Renal or hepatic disease, Hypovolemic or Hypovolemic patients, Patients on diuretics or cardioactive drugs interfering with haemodynamic responses.
In SV, sigmoid gangrene is seen in 6.1-30.2% of all patients and in 10.7-93.4% of surgically treated cases.1,2 Well-known factors affecting bowel gangrene development are the presence of major comorbidities (e.g., cardio-vascular diseases), shock (hypovolemic and/or toxic), delayed admission to the hospital, over-rotation (twisting degree>360Adeg), and ileosigmoid knotting.2,3,11,12
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.